Trade Names:Aralen Phosphate- Tablets 500 mg chloroquine phosphate (equivalent to 300 mg base)Aralen (Canada)
Inhibits parasite growth, possibly by concentrating within parasite acid vesicles, raising pH.
Rapidly and almost completely absorbed from the GI tract.
About 55% bound to nondiffusable plasma constituents. Distributed considerably into tissues (ie, liver, spleen, kidney, lung) and to a lesser extent into brain and spinal cord.
The main metabolite is desethylchloroquine.
Slowly excreted, but increased by acidification of the urine. A small amount is excreted in the feces. About 25% of the dose is excreted in urine as desethylchloroquine. More than 50% of urinary drug product is unchanged chloroquine.
Prophylaxis and treatment of acute attacks of malaria caused by Plasmodium vivax , Plasmodium malariae , Plasmodium ovale , and susceptible strains of Plasmodium falciparum ; extraintestinal amebiasis.
Treatment of rheumatoid arthritis, systemic and discoid lupus erythematosus, porphyria cutanea tarda, scleroderma, pemphigus, lichen planus, polymyositis, and sarcoidosis.
Retinal or visual field changes.
Doses are listed in base equivalents.Acute MalariaAdults
PO Initial dose is 600 mg, then 300 mg 6 h later and 300 mg every day for 2 days.Children
PO Initial dose is 10 mg/kg, then 5 mg/kg 6 h later and 5 mg/kg every day for 2 days.Malaria SuppressionAdults
PO 300 mg base.Children
5 mg/kg/dose (max 300 mg base) weekly. Begin 1 to 2 wk prior to exposure and continue for 4 wk after leaving endemic area. If suppressive therapy is not begun prior to exposure, double initial loading dose and give in 2 divided doses 6 h apart.Extraintestinal AmebiasisAdults
PO 600 mg base/day for 2 days, then 300 mg base/day for 2 to 3 wk.
Store in airtight, light-resistant container at room temperature.
May increase chloroquine serum concentration.Kaolin aluminum or magnesium trisilicate antacids
May decrease GI absorption of chloroquine.Rabies vaccine
Coadministration of intradermally administered rabies vaccine and chloroquine may result in diminished antibody response to vaccine. In this situation CDC recommends administering rabies vaccine IM.
None well documented.
Hypotension; ECG changes.
Headache; neuropathy; seizures; psychotic episodes.
Pruritus; pigment changes; skin eruptions.
Visual disturbances; retinal damage and deafness with prolonged high-dose use; tinnitus.
Anorexia; nausea; vomiting; diarrhea; abdominal cramps.
Agranulocytosis; blood dyscrasias; aplastic anemia.
Perform periodic neuromuscular examinations and notify patient if knee and ankle reflexes are weak.Adverse reactions
If sore throat, fever, weakness, fatigue, or unusual bleeding or bruising occurs, notify health care provider.
Category D .
Excreted in breast milk.
Especially sensitive to adverse reactions; do not exceed recommended dose.
Monitor patients with hepatic disease or alcoholism, or taking other hepatotoxic medications for evidence of worsening liver function such as bleeding.
May induce hemolysis in presence of infection or stressful condition.
May need to discontinue therapy if muscle weakness occurs.
May be exacerbated.
Irreversible retinal damage has occurred.
Headache, drowsiness, visual disturbances, CV collapse, seizures, respiratory and cardiac arrest, death.
Copyright © 2009 Wolters Kluwer Health.